Home / Media Center / News / TRINITY LIFE SCIENCES UNVEILS BREAKTHROUGH AI MODEL THAT DETECTS TYPE 1 DIABETES A YEAR BEFORE SYMPTOMS APPEAR
“Identification of Earlier Stage Autoimmune Type 1 Diabetes Using Machine Learning Algorithms” study featured at American Diabetes Association’s 85th Scientific Sessions
Waltham, MA, July 17, 2025 – Trinity Life Sciences, a leader in advisory, insights and analytics for the life sciences industry, presented results from a new study demonstrating the potential of an artificial intelligence and machine learning (AIML) model to detect type 1 diabetes (T1D) at least one year before a patient’s clinical diagnosis. Leveraging Trinity’s leading-edge AI capabilities and deep therapeutic expertise, with support from Sanofi, the model also maintains improved accuracy compared to traditional T1D screening methods.
The retrospective cohort study, Identification of Earlier Stage Autoimmune Type 1 Diabetes Using Machine Learning Algorithms, conducted by Trinity and Sanofi, aimed to develop a predictive machine learning model that could identify individuals at high risk of progression to stage 3 T1D. An integrated healthcare open claims (e.g., anonymized patient demographics, conditions, symptoms, treatments, etc.) and lab data set was used to develop the model. It was trained and validated using data from confirmed T1D patients, focusing on both pediatric and adult populations.
Key findings of the study:
- With a 12-month blinded period built into its design, the model demonstrated the ability to identify potential T1D cases at least one year before formal diagnosis.
- The model balances sensitivity and accuracy, prioritizing the ability to capture as many true positive cases as possible while minimizing false positives.
- The model is more likely to identify adult T1D populations than pediatric ones, which differs from typical healthcare practices.
- By targeting higher risk individuals, the approach aims to modernize T1D screening strategies and improve patient outcomes.
“We are thrilled to collaborate with Sanofi on this groundbreaking study,” said Clare Gora, Partner & Head of Data Strategy & Analytics at Trinity Life Sciences. At Trinity, we believe the intersection of AI technologies, life sciences expertise and data is where true innovation happens.”
The study, Identification of Earlier Stage Autoimmune Type 1 Diabetes Using Machine Learning Algorithms, was featured in a late-breaking poster session at the American Diabetes Association (ADA) 85th Scientific Sessions held from June 20-23 in Chicago, Illinois.
About Trinity Life Sciences
With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit TrinityLifeSciences.com.
Clare Gora, Partner & Head of Data Strategy & Analytics at Trinity Life Sciences
Media Contact:
Richard Lorenzen
Fifth Avenue Brands
rlorenzen@fifthavenuebrands.com
Sign up for the latest intelligence
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.